SWOG clinical trial number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Open
Phase
Abbreviated Title
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Status Notes
CTSU/A012301 is nearing the protocol-specified accrual target and will be temporarily closed to new patient enrollment. Effective Friday, January 23, 2026, at 4:30 PM ET, no additional patients will be enrolled.

CTSU/A012301 has been endorsed and activated by SWOG, effective 05/06/2025. CTSU/A012301 was activated by Alliance, effective 02/05/2025.
Activated
02/05/2025
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Breast Cancer

Treatment

Tamoxifen Letrozole Anastrozole Exemestane

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012303

Shortstop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer who Achieve PCR After Neoadjuvant Chemotherapy with HER2 Blockade
Research Committee(s)
Breast Cancer
Activated
07/25/2025
Open
SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Management and Survivorship
Activated
10/30/2023
Accrual
31%
Open
Phase